No data available.
Please log in to see this content.
You have no subscription access to this content.
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.
Chemoradiotherapeutic wrinkled mesoporous silica nanoparticles for use in cancer therapy
1.K. Andrieux, J. Nicolas, L. Moine, and G. Barratt, Polymeric Nanoparticles for Drug Delivery (CRC Press, 2013), Vol. 2, p. 123.
2.G. Gellerman and M. A. Firer, Targeted Drug Delivery in Cancer Therapeutics (Transworld Research Network, Kerala, 2010), Vol. 185.
3.R. Padmavathy and M. Hariharan, Res. J. BioTechnol. 3, 117 (2008).
4.F. N. Ludwig, S. D. Pacetti, S. F. A. Hossainy, and D. Davalian, “Nanoshells comprising self-assembled material for drug delivery,” U.S. patent 20070292495A1 (20 December 2007).
5.A. Gabizon, Ann. Biol. Clin. 51, 811 (1993).
10.B. Sivakumar, R. G. Aswathy, R. Sreejith, Y. Nagaoka, S. Iwai, M. Suzuki, T. Fukuda, T. Hasumura, Y. Yoshida, T. Maekawa, and D. N. Sakthikumar, J. Biomed. Nanotechnol. 10, 885 (2014).
11.D. Zhang, C. Yuan, and H. Zhang, “Composite magnetic nanoparticle for targeting therapy for liver cancer and its preparation method,” CN103611168A (2014).
12.J. Jung, S.-J. Park, H. K. Chung, H.-W. Kang, S.-W. Lee, M. H. Seo, H. J. Park, S. Y. Song, S.-Y. Jeong, and E. K. Choi, Int. J. Radiat. Oncol., Biol., Phys. 84, e77–e83 (2012).
13.A. Z. Wang, K. Yuet, L. Zhang, F. X. Gu, M. Huynh-Le, A. F. Radovic-Moreno, P. W. Kantoff, N. H. Bander, R. Langer, and O. C. Farokhzad, Nanomedicine 5, 361 (2010).
14.Z. Long, M. Q. Xie, T. Zhang, H. Shen, X. Q. Xu, and L. Guo, J. South. Med. Univ. 29, 1827 (2009).
16.J. H. Tian, B. X. Xu, J. M. Zhang, B. W. Dong, P. Liang, and X. D. Wang, J. Nucl. Med. 37, 958 (1996).
17.R. J. Mumper, U. Y. Ryo, and M. Jay, J. Nucl. Med. 32, 2139 (1991).
18.W. Bult, P. R. Seevinck, G. C. Krijger, T. Visser, L. M. J. Kroon-Batenburg, C. J. G. Bakker, W. E. Hennink, A. D. Van Het Schip, and J. F. W. Nijsen, Pharm. Res. 26, 1371 (2009).
19.S. W. Zeilhuis, J. H. Seppenwoolde, C. J. G. Bakker, U. Jahnz, B. A. Zonnenberg, A. D. Van Het Schip, W. E. Hennink, and J. F. W. Nijsen, J. Biomed. Mater. Res., Part A. 82, 892 (2007).
20.J. K. Kim, K. H. Han, J. T. Lee, Y. H. Paik, S. H. Ahn, J. D. Lee, K. S. Lee, C. Y. Chon, and Y. M. Moon, Clin. Cancer Res. 12, 543 (2006).
21.A. J. Di Pasqua, H. Yuan, Y. Chung, J. K. Kim, J. E. Huckle, C. Li, M. Sadgrove, T. H. Tran, M. Jay, and X. Lu, J. Nucl. Med. 54, 111 (2013).
37.C. E. Ashley, E. C. Carnes, G. K. Phillips, D. Padilla, P. N. Durfee, P. A. Brown, T. N. Hanna, J. Liu, B. Phillips, M. B. Carter, N. J. Carroll, X. Jiang, D. R. Dunphy, C. L. Willman, D. N. Petsev, D. G. Evans, A. N. Parikh, B. Chackerian, W. Wharton, D. S. Peabody, and C. J. Brinker, Nat. Mater. 10, 389 (2011).
38.E. C. Dengler, J. Liu, A. Kerwin, S. Torres, C. M. Olcott, B. N. Bowman, L. Armijo, K. Gentry, J. Wilkerson, J. Wallace, X. Jiang, E. C. Carnes, C. J. Brinker, and E. D. Miligan, J. Controlled Release 168, 209 (2013).
43.R. G. Krishan, “Catalysis by polymer supported dendrimers, their metal complexes and nanoparticle conjugates,” Ph.D. thesis, Cochin University of Science and Technology, Kochi-22, India, 2008.
47.V. Polshettiwar and J. M. Basset, “High Surface Area Fibrous Silica Nanoparticles,” U.S. patent 20110253643A1 (20 October 2011).
See supplementary material at http://dx.doi.org/10.1063/1.4899118
for FTIR spectra of 165
Ho-MS np before and after surfactant removed and CPB surfactant, TEM image of formation of 165
Ho-MS np after 6 h, 12 h, 18 h, and 21 h reaction times at 70 °C, secondary electron images for Si, Ho, and O mapping and elemental spectrum of 165
Ho-MS np, percentage variation of cisplatin drug loading in to 165
Ho-MS np with the time, EDX mapping and spectrum of cisplatin loaded Ho-MS, carboplatin loaded Ho-MS and oxaliplatin loaded Ho-MS, size distribution curve of DOPC-165
Ho-MS and 165
Ho-MS np in simulated body fluid solution and digital image of the DOPC-165
Ho-MS dispersion, zeta potential measurements of DOPC-165
Ho-MS-cisplatin np, DOPC-165
Ho-MS-carboplatin np and DOPC-165
Ho-MS-oxaliplatin np.[Supplementary Material]
49.Z. Wang, B. Chen, G. Quan, F. Li, Q. Wu, L. Dian, Y. Dong, G. Li, and C. Wu, Int. J. Nanomed. 7, 5807 (2012).
59.J. D. X. Bradley, J. R. Roti, and S. Mutic, “Principles and practice of radiation therapy,” in The Washington Manual of Oncology, 2nd ed., edited by R. Govindan (Lippincott Williams & Wilkins, 2007).
65.S. Dash, P. N. Murthy, L. Nath, and P. Chowdhury, Acta Pol. Pharm. Drug Res. 67, 217 (2010).
Article metrics loading...
Over the last decade, the development and application of nanotechnology in cancer detection, diagnosis, and therapy have been widely reported. Engineering of vehicles for the simultaneous delivery of chemo- and radiotherapeutics increases the effectiveness of the therapy and reduces the dosage of each individual drug required to produce an observable therapeutic response. We here developed a novel chemoradiotherapeutic 1,2-dioleoyl-sn-glycero-3-phosphocholine lipid coated/uncoated platinum drug loaded, holmium-containing, wrinkled mesoporous silica nanoparticle. The materials were characterized with TEM, FTIR, 1H NMR, energy dispersive x-ray, inductively coupled plasma-mass spectrometry, and zeta potential measurements. In vitro platinum drug release from both lipid coated and uncoated chemoradiotherapeutic wrinkled mesoporous silica are reported. Various kinetic models were used to analyze the release kinetics. The radioactivity of the chemoradiotherapeutic nanocarriers was measured after neutron-activation.
Full text loading...
Most read this month